Table 2 Comparison of Week 30 GIA levels in malaria-naive and malaria-exposed adults.

From: Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses

Ag

Comparison

Difference (95% CI)

p-value

GIA naive (95% CI)

GIA exposed (95% CI)

FCR3

F AlOH vs. BF Saline

−12.5 (−32.3 to 7.3)

0.348

24.6 (14.4 to 34.8)

37.1 (26.9 to 47.2)

FCR3

F GLA-SE vs. BF Saline

1.4 (−20.5 to 23.2)

0.998

38.4 (25.7 to 51.1)

37.1 (26.9 to 47.2)

FCR3

F AlOH vs. BF GLA-SE

−24.4 (−44.2 to −4.6)

0.01

24.6 (14.4 to 34.8)

49.0 (35.7 to 62.3)

FCR3

F GLA-SE vs. BF GLA-SE

−10.6 (−32.4 to 11.3)

0.576

38.4 (25.7 to 51.1)

49.0 (35.7 to 62.3)

3D7

F AlOH vs. BF Saline

2.8 (−22.1 to 27.6)

0.991

26.6 (14.0 to 39.2)

23.8 (11.1 to 36.6)

3D7

F GLA-SE vs. BF Saline

−2.8 (−30.3 to 24.7)

0.993

21.0 (5.1 to 37.0)

23.8 (11.1 to 36.6)

3D7

F AlOH vs. BF GLA-SE

−13.7 (−38.9 to 11.6)

0.482

26.6 (14.0 to 39.2)

40.3 (23.3 to 57.2)

3D7

F GLA-SE vs. BF GLA-SE

−19.2 (−47.0 to 8.6)

0.268

21.0 (5.1 to 37.0)

40.3 (23.3 to 57.2)

  1. Post vaccination percent-point differences in GIA levels with corresponding 95% confidence intervals for naive- and malaria-exposed volunteers. p-values are adjusted for multiple comparisons within antigen by Tukey’s post hoc test. Italics indicates statistically significant differences.
Back to article page